Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity. It is an experiemental medicine that is not approved for any use, developed by Gilead. Remdesivir has demonstrated in vitro and in vivo activity in animal models against MERS and SARS, which are also coronaviruses. The preliminary data indicates that remdesivir may have potential activity against COVID-19.
You must be logged in to reply to this topic.
For comments and inquiries about the COVID-19 Pharmacology Resource Center, please fill out the Contact Us form, and we will be in touch shortly.